Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

FDA approves Qelbree for the treatment of ADHD in pediatric patients

April 6, 2021

Ionis initiates phase III study of ION-363

April 6, 2021

BenevolentAI Bio patents tyrosine-protein kinase ABL1 inhibitors

April 6, 2021

GPR68 targeting is protective against ischemic stroke in mice

April 6, 2021

First patient dosed in phase II study of ABP-450 as treatment of cervical dystonia

April 6, 2021

Microglial EZH2 inhibition may protect against stroke damage

April 6, 2021

FDA issues complete response letter for sNDA of pimavanserin

April 6, 2021

Phase II data reported for GV-1001 in moderate to severe Alzheimer's disease

April 6, 2021

Tsukushi protein mutations can lead to hydrocephalus

April 1, 2021

Dosing begins in phase Ib study of FX-301 for management of postoperative pain

April 1, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 20, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
WHO declares Ebola outbreak a public health emergency of international concern
BioWorld
The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...
Nxera Pharma prepares and tests new GPR17 antagonists
BioWorld Science
Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...